Study of the Level of Matrix Metalloproteinase-9 as an Indicator of Activity of Inflammatory Process Among Patients Suffering from Multiple Sclerosis
DOI:
https://doi.org/10.53933/sspmpm.v5i2.184Keywords:
multiple sclerosis, diagnosis, matrix metalloproteinase-9, remitting course, progressive course, pharmacotherapyAbstract
Multiple Sclerosis progresses in Ukraine as a cause of disability of young people in conditions of martial law. The role of matrix metalloprotease-9 in the development of the inflammatory process in different types of multiple sclerosis is considered. A study of the level of matrix metalloprotease-9 was conducted in 135 patients with multiple sclerosis with different types of course and at different stages of activity of the pathological process. Higher levels of matrix metalloprotease-9 were found in patients with the remitting type of the disease at the stage of exacerbation, while in patients with the primary-progressive type of the disease this indicator was the lowest. The study of the level of matrix metalloprotease-9 allows us to judge the degree of severity of the inflammatory process and serves as a means of monitoring the effectiveness of multiple sclerosis therapy. It requires a pharmacoeconomic study of the stages of clinical monitoring of patients using a complex of pharmacotherapeutic measures and drugs. The data of the World Health Organization on additions to the Essential Medicines List and the Essential Medicines List for Children with innovative drugs for the treatment of multiple sclerosis, improving the health of the population worldwide, WHO Recommendations and ICD-11 require the development of the issue for the publication of the monograph "Medicines for neurologists, psychiatrists and narcologists" in a new edition.
References
There are about 30 thousand patients with multiple sclerosis in Ukraine. Patients of Ukraine. 29.05.2024. URL: https://www.facebook.com/patients.org.ua/posts/%D0%B2BD/848297437327074/
In Ukraine, the incidence of multiple sclerosis is critical - expert. Ukrinform. 28.05.2021. URL: https://www.ukrinform.ua/rubric-society/3254974-v-ukraini-pokazniki-zahvoruvanosti-na-rozsianij-skleroz-e-kriticnimi-eksperti.html
Sokolova N. What you need to know about multiple sclerosis: an expert explains. Ministry of Health of Ukraine. 2025. URL: https://moz.gov.ua/uk/scho-treba-znati-pro-rozsijanij-skleroz-pojasnjue-ekspert
Berezivska S. Woke up semi-paralyzed: a dangerous disease is spreading in Ukraine due to the war. TSN. 29.05.2024. URL: https://tsn.ua/exclusive/prokinulasya-napivparalizovanoyu-v-ukrayini-cherez-viynu-poshiryuyetsya-nebezpechna-hvoroba-2589252.html
Order of the Ministry of Health of Ukraine dated January 13, 2025 No. 86 “On bringing to the state enterprise “Medical Procurement of Ukraine” the list of areas of prevention, diagnostics and treatment for 2025”. Ministry of Health of Ukraine. 13.01.2025. URL: https://moz.gov.ua/uk/decrees/nakaz-moz-ukrayini-vid-13-01-2025-86-pro-dovedennya-do-derzhavnogo-pidpriyemstva-medichni-zakupivli-ukrayini-pereliku-napryamiv-profilaktiki-diagnostiki-ta-likuvannya-2025-roku
Order of the Ministry of Health of Ukraine dated 13.01.2023 No. 76 “On bringing to the state enterprise “Medical Procurement of Ukraine” the list of areas of prevention, diagnostics and treatment for 2023. Verkhovna Rada of Ukraine. Editorial dated November 24, 2023. URL: https://zakon.rada.gov.ua/rada/show/v0076282-23#Text
Order of the Department of Health dated December 19, 2024 No. 1193 “On the distribution of medicines for the treatment of patients with multiple sclerosis, purchased from the budget of Kyiv for 2024”. Department of Health of the executive body of the Kyiv City Council (Kyiv City State Administration). 2024. URL: https://health-2023.kyivcity.gov.ua/files/2024/12/20/1193.PDF
Ciccarelli O., Barkhof F., Bodini B. et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. The Lancet Neurology. 2014. Vol. 13. Iss. 8. P. 807-822. URL: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70101-2/abstract DOI: https://doi.org/10.1016/S1474-4422(14)70101-2
Dubrov S.O., Negrych T.I., Voloshyna N.P. et al. New clinical protocol of medical care “Multiple sclerosis in adults”. Approved by Order of the Ministry of Health of Ukraine dated July 1, 2024 No. 1142. 205 p.URL: https://moz.gov.ua/storage/uploads/198b262f-05d0-49b2-abcf-9d1a78a7a6a5/dn_1142_01072024_dod.pdf
Shapovalov V., Shapovalova V., Osyntseva A. et al. Multidisciplinary context of research of a new drug in infectious and inflammatory diseases. Annals of Mechnikov’s Institute. 2024. No. 3. Р. 3-9. DOI: https://doi.org/10.5281/zenodo.13820208
Vasylovskyy V., Nehreba T., Voloshyna N. et al. Application of Glucocorticoids in Therapy of Multiple Sclerosis. SSP Modern Pharmacy and Medicine. 2024. Vol.4. No.2. P. 1-14. DOI: https://doi.org/10.53933/sspmpm.v4i2.141
Vasylovskyy V., Nehreba T., Voloshyna N. et al. Application of Glucocorticoids in Therapy of Multiple Sclerosis. SSP Modern Pharmacy and Medicine. 2024. Vol. 4. No. 2. Р. 1-14. DOI: https://doi.org/10.53933/sspmpm.v4i2.141. DOI: https://doi.org/10.53933/sspmpm.v4i2.141
Shapovalova V. Post-Traumatic Stress Disorder: Administration, Clinical and Pharmacological, Organizational and Legal, Pharmaceutical Management, Recent Case Studies. SSP Modern Pharmacy and Medicine. 2024. Vol. 4. No. 1 P. 1–8. DOI: https://doi.org/10.53933/sspmpm.v4i1.123 DOI: https://doi.org/10.53933/sspmpm.v4i1.123
Chernenko M., Nehreba T., Voloshyna N. et al. Modern Pulse Corticosteroid Therapy in Patients with Multiple Sclerosis: Adverse Events and Clinical and Pharmacological Measures to Eliminate Them. SSP Modern Pharmacy and Medicine. 2025. Vol. 5. No. 1. P. 1-15. DOI: https://doi.org/10.53933/sspmpm.v5i1.173 DOI: https://doi.org/10.53933/sspmpm.v5i1.173
Shapovalova V. Extemporaneous Preparations in the Pharmacotherapy of Nervous System Disorders: Pharmaceutical Management, Marketing, Analysis, Application. SSP Modern Pharmacy and Medicine. 2023. Vol. 3. No. 4. P. 1-7. DOI: https://doi.org/10.53933/sspmpm.v3i4.111 DOI: https://doi.org/10.53933/sspmpm.v3i4.111
Vasylovskyy V., Nehreba T., Chernenko M. et al. Modern Experience of Pharmacotherapeutic Use and Effectiveness of Endolumbal Administration of Glucocorticoids in Progressive Types of Course for Multiple Sclerosis. SSP Modern Pharmacy and Medicine. 2024. Vol. 4. No. 3. P. 1-10. DOI: https://doi.org/10.53933/sspmpm.v4i3.157 DOI: https://doi.org/10.53933/sspmpm.v4i3.157
Shapovalova V. Pharmacotherapy of Depressive Disorders in Conditions of Coronavirus Disease: Pharmacoeconomic Experimental Study. SSP Modern Pharmacy and Medicine. 2023. Vol. 3. No. 3. 1–11. DOI: https://doi.org/10.53933/sspmpm.v3i3.101 DOI: https://doi.org/10.53933/sspmpm.v3i3.101
Understanding Multiple Sclerosis. Brain Institute – OHSU. 2025. URL: https://www.ohsu.edu/brain-institute/understanding-multiple-sclerosis
Gusev Ie.I., Boiko A.N. Multiple Sclerosis: From Immunopathogenesis Studies to New Treatment Methods. M.: Gubernskaya meditsina. 2001. 101 p.
Kicherova О.А., Reichart L.I., Bychenko S.M. Multiple sclerosis. Tyumen: City-press. 2007. 152 p.
Kesserling J. Multiple sclerosis. Cambrig University Presse. 1997. 214 p. URL: https://books.google.com.ua/books/about/Multiple_Sclerosis.html?id=BniOWOTTLdUC&redir_esc=y
Takashi I., MatsushigeТ., Takasu Т. et al. Cerebrospinal fluid levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in subacute sclerosing panencephalitis. Journal of Infection. Vol. 56. Iss. 5. Р. 376-380. URL: https://www.journalofinfection.com/article/S0163-4453(08)00099-6/abstract DOI: https://doi.org/10.1016/j.jinf.2008.02.014
Clements J.M., Cossins J.A., Wells G.M. et. al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-α inhibitor. J. Immunol. Vol. 1997. Vol. 74. Iss. 1. Р. 85-94. URL: https://www.jni-journal.com/article/S0165-5728(96)00210-X/abstract DOI: https://doi.org/10.1016/S0165-5728(96)00210-X
Ries C., Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe Seyler. 1995. Vol. 376. No. 6. Р. 345-355. URL: https://pubmed.ncbi.nlm.nih.gov/7576228/
Goetzl E.J., Banda M.J., Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 1996. Vol.156. No.1. P.1-4. URL: https://pubmed.ncbi.nlm.nih.gov/8598448/ DOI: https://doi.org/10.4049/jimmunol.156.1.1
Yong V.W., Krekoski C.A., Forsyth P.A. et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998. Vol. 21. P. 75-80. DOI: https://doi.org/10.1016/S0166-2236(97)01169-7
Paul R., Lorenzl S., Koedel U et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 1998. Vol. 44. Iss. 4. P. 592-600. URL: https://pubmed.ncbi.nlm.nih.gov/9778257/ URL: https://onlinelibrary.wiley.com/doi/10.1002/ana.410440404
Leppert D., Waubant E., Galardy R. T-cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 1995. Vol. 154. Issue 9. P. 4379-4389. URL: https://pubmed.ncbi.nlm.nih.gov/7722295/ DOI: https://doi.org/10.4049/jimmunol.154.9.4379
Luiz G. Matrix Metalloproteinases: from molecular mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacological Reviews. Vol. 74. Iss. 3. Р. 714-770. URL: https://pharmrev.aspetjournals.org/article/S0031-6997(24)00723-3/fulltext DOI: https://doi.org/10.1124/pharmrev.121.000349
Gottschall P.E., Deb S. Regulation of matrix metalloproteinase expression in astrocytes, mikroglia and neurons. Neuroimmunomodulation. 1996. Vol. 3. Iss. 2-3. P. 69-75. DOI: https://doi.org/10.1159/000097229 DOI: https://doi.org/10.1159/000097229
Kaur К., Allahbadia G., Singh М. An Update on Role of Matrix Metalloproteinases in the Central Nervous System in health along with various diseases –implications in treating brain tumours as well-A Systematic Review. Journal of Clinical Case Reports and Clinical Study. Vol. 2. No. 2. 2021. Р. 1-19. URL: https://aditum.org/journals/clinical-case-reports-and-clinical-study/archive/68 DOI: https://doi.org/10.61148/2766-8614/JCCRCS/021
Behl T., Kaur G., Sehgal A. et al. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. Int. J. Mol. Sci. 2021. Vol. 22. No. 3. H. 1413. DOI: https://doi.org/10.3390/ijms22031413 DOI: https://doi.org/10.3390/ijms22031413
Thompson A.J., Polman Ch., Hohlfeld R. Multiple sclerosis. Clinical challengers and controversies. London. 1997. 539 p.
Paul R., Lorenzl S., Koedel U et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 08.10.2004. Vol. 44. P.592-600. DOI: https://doi.org/10.1002/ana.410440404 DOI: https://doi.org/10.1002/ana.410440404
Paty D., Ebers G.S. Multiple sclerosis. Philadelphia. 1998. 572 p.
“The disease of a thousand faces”: multiple sclerosis and treatment methods in young people. Department of Health of the Poltava Regional State Administration. 05/25/2022. URL: http://uoz.gov.ua/2022/05/25/%D1%85%D0%B2%D0%BE%D1%80%D0%BE%D0%B1%D0%B0-%D1%82%D0%B8%D1%81%D1%8F%D1%87%D1%96-%D0%BE%D0%B1%D0%BB%D0%B8%D1%87-%D1%80%D0%BE%D0%B7%D1%81%D1%96%D1%8F%D0%BD%D0%B8%D0%B9-%D1%81%D0%BA%D0%BB/
The Verkhovna Rada of Ukraine adopted the Law, which extended the term of martial law in Ukraine. official web portal of the parliament of the Verkhovna Rada of Ukraine Published. 15.01.2025. URL: https://www.rada.gov.ua/news/razom/257695.html
Department of Autoimmune and Degenerative Diseases of the Nervous System. Multiple Sclerosis Center. State Institution INPN named after P.V. Voloshin NAMS of Ukraine. 2024. URL: https://inpn.org.ua/departments/2
Filippi M., Bar-Or A., Piehl F. et al. Multiple sclerosis. Nat. Rev. Dis. 2018. Vol.4. Iss. 43. DOI: https://doi.org/10.1038/s41572-018-0041-4 DOI: https://doi.org/10.1038/s41572-018-0041-4
Multiple sclerosis. Medinfo. 30.05.2024. URL: https://medinfo.zp.ua/ua/novosti_mediciny_zaporozhya/rassejannyj-skleroz-v-cifrah/
New information resource: Wellness practices and complementary therapies. MSIF. 27.03.2025. URL: https://www.msif.org/news/2025/03/25/wellness-practices-and-complementary-therapies/
Shapovalova V. The ICD-11 for the twenty-first century: the first view from the organizational, legal, clinical and pharmacological aspects. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. Nо.1. P. 1-13. URL: https://doi.org/10.53933/sspmpm.v2i1.37 DOI: https://doi.org/10.53933/sspmpm.v2i1.37
WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis. WHO. 26.06.2023. URL: https://www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosis
Shapovalova V.A., Sosyn I.K., Butenko G.M. et al. Pharmaceutical law in narcology. Kharkov: “Fact”. 2004. 800 p
Shapovalova V.A., Voloshyn P.V., Stefanov A.V. et al. Medicines for neurologists, psychiatrists and narcologists. Kh.: «Fakt». 2003. 784 p.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maksym Chernenko, Nataliya Voloshyna, Vitaliy Vasylovskyy, Tetiana Nehreba, Tetiana Pohulaieva, Ivan Voloshyn-Haponov
This work is licensed under a Creative Commons Attribution 4.0 International License.
